Search Login Register

Dermatofibrosarcoma Summary

Description: A fibrosarcoma of the skin, beginning most often as an indurated nodule that grows slowly and hence is often ignored until it grows large. Dermatofibrosarcomas show an extremely aggressive tendency to invade local surrounding tissue. They do not metastasize, however, even after multiple recurrences. About 50% will recur after simple incision; hence wide excision should be resorted to. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1356)

Also Known As: Dermatofibrosarcomas

Networked: 44 relevant articles (3 outcomes, 5 trials/studies) for this Disease

Key Drugs and Agents for Dermatofibrosarcoma

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. imatinib (Gleevec) : 2 outcomes 3 studies in 8 results : FDA 3
  2. sunitinib (Sutent) : 1 outcome 1 study in 2 results : FDA 2
  3. Dermatofibrosarcoma protuberans : 1 study in 7 results : IBA
  4. Proteins (Proteins, Gene) : 1 study in 2 results : IBA
  5. Platelet-Derived Growth Factor : 1 study in 1 result : IBA
  6. Collagen : 1 study in 1 result : IBA
  7. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor) : 2 results : IBA
  8. Paraffin : 2 results : IBA
  9. Factor XIIIa : 1 result : IBA
  10. Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity) : 1 result : IBA
Show All >>

Diseases Related to Dermatofibrosarcoma

  1. Neoplasms (Cancer)
  2. Leiomyosarcoma
  3. Fibrosarcoma
  4. Sarcoma (Soft Tissue Sarcoma)
  5. Liposarcoma
Show All >>

Key Therapies for Dermatofibrosarcoma

Efficacy Chart >>
  1. Sutures (Suture) : 1 outcome in 2 results
  2. Neoadjuvant Therapy : 1 study in 1 result
  3. Radiotherapy : 4 results
  4. Bariatric Surgery : 1 result
  5. Transplants (Transplant) : 1 result
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.